Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
212
datasets available to search
ShareScore release 0.9.0
Dataset results
212 results for “ivermectin”
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
ClinicalTrials.gov study NCT04056325. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Does ivermectin treatment for endemic hookworm infection alter the gut microbiota of endangered Australian sea lion pups?
Open the record for dataset details and reuse information.
Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicenter, assessor-blinded, cluster-randomised clinical trial
Open the record for dataset details and reuse information.
Single versus multiple dose ivermectin regimen in onchocerciasis-infected persons with epilepsy treated with phenobarbital: a randomized clinical trial in the Democratic Republic of Congo
<p>Open data for a randomized clinical trial performed in onchocerciasis-endemic villages of the Logo health zone in Ituri province in the Democratic Republic of Congo where mass ivermectin administration had never been implemented. Ivermectin naïve, persons with epilepsy with <em>Onchocerca volvulus</em> infection were randomly allocated to receive ivermectin once, twice or thrice over a one year period of follow up. At the same time they were treated with the anti-epileptic drug phenobarbital. At baseline, information was collected on seizure semiology, seizure frequency, epilepsy risk factors, relevant medical history, previous AED and ivermectin use. The primary outcome was seizure freedom during the last four months of the 12-month follow up period.</p>
An in silico docking simulation of SARS Coronavirus2 and Ivermectin
<p><strong>ABSTRACT</strong></p> <p> COVID-19 is spreading and infecting in the world. And that is occurring a death very much. Of course, I want to cooperate for save peoples. And I was simulating a docking about proteins of SARS Coronavirus 2 in silico. That a papain-like protease, a karyopherin importin α,β and RNA Polymerase. One hypothesis [1] said Ivermectin can destabilises about a bind to an importin and the virus cargo proteins. And I got a significantly results from in silico simulation that at catalytic center of RNA Polymerase. Remdesivir is docking at here. [2] I dedicate this report to a current patients and a future patients.</p> <p><strong>1. Introduction</strong></p> <p> The virus is called the bacteriophage. You know that the virus infect the bacteria. Therefore, the bacteria need a counter plan. I think, Ivermectin(Avermectin) is that. One hypothesis, the Coronavirus2 is<br> replicating by using a main protease [4], papain-like protease [4] and this RNA Polymerase. And Ivermectin destablishes about bind to an importin and the virus cargo proteins [1]. I checked for these case. But I<br> seems that Importin is too big for Ivermectin. And netxt, I checked for RNA Polymerase. and I report this result simply.</p> <p><strong>2. A software for docking simulation</strong></p> <p> This case is using a software that “Autodock vina” [5]. This software is better performance than other docking simulation softwares. But a simulation accuracy isn’t a high quality more than a real phenomenon<br> yet. This software is using an affinity score [kcal/mol]. See also vina web-site [5].</p> <p><strong>3. A docking parameters and Dataset</strong></p> <p> This case is using following parameters for docking simulations.</p> <p>(1).exhaustiveness: 8<br> (2).num modes: 10<br> (3).energy range: 1</p> <p>and I was using a protein data PDB:7bzf for RNA Polymerase. And PDB:IVM for Ivermectin. I chosen a chain A from PDB:7bzf by using pymol [8]. And I converted PDB:IVM from .sdf to .pdb by using “PDB<br> format-PDBx/mmCIF conversion service” web-site [9].</p> <p><strong>4. Contents</strong></p> <p> Figure 2: Front view of RNA Polymerase and Ivermectin I tried to a docking simulation during a four monthes about RNA Polymerase (PDB:7bzf) of SARS Coronavirus2 and Ivermectin [6]. And<br> I got a significantly results. I chosen a few higher score to following.</p> <p>mode | affinity | dist from best mode<br> | (kcal/mol) | rmsd l.b.| rmsd u.b.<br> -----+------------+----------+----------<br> 1 -11.5 0.000 0.000<br> 2 -11.1 1.975 3.233<br> 3 -11.0 1.895 2.482</p> <p>mode | affinity | dist from best mode<br> | (kcal/mol) | rmsd l.b.| rmsd u.b.<br> -----+------------+----------+----------<br> 1 -11.4 0.000 0.000<br> 2 -11.0 1.572 2.041<br> 3 -10.8 4.406 14.971</p> <p>mode | affinity | dist from best mode<br> | (kcal/mol) | rmsd l.b.| rmsd u.b.<br> -----+------------+----------+----------<br> 1 -11.4 0.000 0.000<br> 2 -10.8 1.550 2.430<br> 3 -10.6 1.648 2.197</p> <p>These are a near points. You can see a number of rmsd (Root Mean Square Deviation). These are a catalytic center of RNA Polymerase. One paper said [2], this point can combine Remdesivir too. Figure 1,2,3 are a point of best of affinity score that -11.5[kcal/mol]. Of course, If you want to know detail of results then you can download an all eleven data about this simulation from my web-site.</p> <p><strong>5. Conclusion</strong></p> <p> I seems that is very significantly result. Because, One, here are a higher score point (Figure 4). Second, here are a catalytic center. Third, Remdesivir can combine at same point [2]. I consider about an accuracy<br> of Autodoc Vina and a conformation will change, probably. You know, this is a computer simulation absolutely. I want to wait a result of cryo-EM and a crystal structure complex.</p> <p><strong>Acknowledge</strong></p> <p> Thank you for the NIG supercomputer at ROIS National Institute of Genetics. Because I’m using this computer system everyday.</p> <p> </p>
Data from: Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian Aboriginal community
Background: Scabies is endemic in many Aboriginal and Torres Strait Islander communities, with 69% of infants infected in the first year of life. We report the outcomes against scabies of two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community. Methods: Utilizing a before and after study design, we measured scabies prevalence through population census with sequential MDAs at baseline and month 12. Surveys at months 6 and 18 determined disease acquisition and treatment failures. Scabies infestations were diagnosed clinically with additional laboratory investigations for crusted scabies. Non-pregnant participants weighing ≥15 kg were administered a single 200 μg/kg ivermectin dose, repeated after 2–3 weeks if scabies was diagnosed, others followed a standard alternative algorithm. Principal Findings: We saw >1000 participants at each population census. Scabies prevalence fell from 4% at baseline to 1% at month 6. Prevalence rose to 9% at month 12 amongst the baseline cohort in association with an identified exposure to a presumptive crusted scabies case with a higher prevalence of 14% amongst new entries to the cohort. At month 18, scabies prevalence fell to 2%. Scabies acquisitions six months after each MDA were 1% and 2% whilst treatment failures were 6% and 5% respectively. Conclusion: Scabies prevalence reduced in the six months after each MDA with a low risk of acquisition (1–2%). However, in a setting where living conditions are conducive to high scabies transmissibility, exposure to presumptive crusted scabies and population mobility, a sustained reduction in prevalence was not achieved. Clinical Trial Registration: Australian New Zealand Clinical Trial Register (ACTRN—12609000654257).
Supplementary File_Ivermectin_Research Integrity Assessment (Version 1)
<p>Supplementary material (Research Integrity Assessment Tool (Version 1)) for the updated Cochrane Review "Ivermectin for preventing and treating COVID-19".</p>
Ivermectin resistance in dung beetles exposed for multiple generations
<p>Datasets and scripts</p>
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
ClinicalTrials.gov study NCT00790998. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Ivermectin Treatment Efficacy in Covid-19 High Risk Patients
ClinicalTrials.gov study NCT04920942. IPD Sharing: NO. Countries: 1. Publications: 1.
Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan
ClinicalTrials.gov study NCT04701710. IPD Sharing: NO. Countries: 1. Publications: 1.
Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)
ClinicalTrials.gov study NCT04894721. IPD Sharing: NO. Countries: 1. Publications: 3.
Ivermectin Versus Albendazole for Chronic Strongyloidiasis
ClinicalTrials.gov study NCT00765024. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
ClinicalTrials.gov study NCT03517462. IPD Sharing: YES. Countries: 1. Publications: 42.
Ivermectin in the Treatment of Head Lice
ClinicalTrials.gov study NCT00819520. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults
ClinicalTrials.gov study NCT02407782. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
ClinicalTrials.gov study NCT01975441. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The
ClinicalTrials.gov study NCT04854460. IPD Sharing: NO. Countries: 1. Publications: 3.
Ivermectin Role in Covid-19 Clinical Trial
ClinicalTrials.gov study NCT04746365. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treatment of Ocular Demodex Infestation With Topical Ivermectin Cream 1%
ClinicalTrials.gov study NCT05213585. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.